Literature DB >> 26179172

Health Beliefs and Co-morbidities Associated with Appointment-Keeping Behavior Among HCV and HIV/HCV Patients.

Pooja Pundhir1, Carol S North2, Oluwatomilade Fatunde1, Mamta K Jain3,4.   

Abstract

Appointment-keeping behavior is an important requisite for HCV linkage and treatment initiation. In this study we examine what impact hepatitis C (HCV) knowledge and attitudes has on appointment-keeping behavior among a cohort of HCV and HCV/HIV patients. Knowledge scores and attitude scales, obtained from a cross-sectional survey, were correlated with proportion of appointments kept 1 year prior to taking the survey. Independent risk factors for missing appointments were examined by multiple regression analysis. 292 HCV patients completed the survey, and 149 (51%) were co-infected with HIV. HCV patients kept 67.5 ± 17.4% of their total appointments and a similar proportion (67 ± 38.2) of Liver Clinic appointments, but they attended a higher proportion (73 ± 24.4) of Primary Care Clinic appointments. However, certain health beliefs, psychiatric illness, and HIV co-infection were independently associated with lower levels of appointment-keeping behavior. HCV knowledge was not associated with appointment-keeping behavior. Health beliefs, psychiatric illness, and HIV co-infection are associated with missing appointments, but no link between knowledge and appointment keeping behavior is apparent. In order to increase engagement into HCV care, HCV care coordination programs need to focus on addressing health beliefs and providing resources to those at highest risk for missing appointments.

Entities:  

Keywords:  Appointment-keeping behavior; HCV; HIV; Health beliefs

Mesh:

Year:  2016        PMID: 26179172     DOI: 10.1007/s10900-015-0059-4

Source DB:  PubMed          Journal:  J Community Health        ISSN: 0094-5145


  25 in total

1.  Barriers to accessing care in patients with chronic hepatitis C: the impact of depression.

Authors:  D M Evon; K M Simpson; D Esserman; A Verma; S Smith; M W Fried
Journal:  Aliment Pharmacol Ther       Date:  2010-09-17       Impact factor: 8.171

2.  Hepatitis C management: the challenge of dropout associated with male sex and injection drug use.

Authors:  Damien J Lowry; John D Ryan; Naeem Ullah; Thomas Barry Kelleher; John Crowe
Journal:  Eur J Gastroenterol Hepatol       Date:  2011-01       Impact factor: 2.566

3.  Knowledge and attitudes about hepatitis C virus (HCV) infection and its treatment in HCV mono-infected and HCV/HIV co-infected adults.

Authors:  E Y Chen; C S North; O Fatunde; I Bernstein; S Salari; B Day; M K Jain
Journal:  J Viral Hepat       Date:  2013-04-01       Impact factor: 3.728

4.  Challenges facing providers caring for HIV/HCV-coinfected patients.

Authors:  Helen-Maria Lekas; Karolynn Siegel; Jason Leider
Journal:  Qual Health Res       Date:  2011-08-08

5.  The dimensionality of stigma: a comparison of its impact on the self of persons with HIV/AIDS and cancer.

Authors:  B L Fife; E R Wright
Journal:  J Health Soc Behav       Date:  2000-03

6.  Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.

Authors:  Mark S Sulkowski; Susanna Naggie; Jacob Lalezari; Walford Jeffrey Fessel; Karam Mounzer; Margaret Shuhart; Anne F Luetkemeyer; David Asmuth; Anuj Gaggar; Liyun Ni; Evguenia Svarovskaia; Diana M Brainard; William T Symonds; G Mani Subramanian; John G McHutchison; Maribel Rodriguez-Torres; Douglas Dieterich
Journal:  JAMA       Date:  2014 Jul 23-30       Impact factor: 56.272

7.  Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors:  Stefan Zeuzem; Ira M Jacobson; Tolga Baykal; Rui T Marinho; Fred Poordad; Marc Bourlière; Mark S Sulkowski; Heiner Wedemeyer; Edward Tam; Paul Desmond; Donald M Jensen; Adrian M Di Bisceglie; Peter Varunok; Tarek Hassanein; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

8.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

Authors:  Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

9.  Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

Authors:  Mark S Sulkowski; David F Gardiner; Maribel Rodriguez-Torres; K Rajender Reddy; Tarek Hassanein; Ira Jacobson; Eric Lawitz; Anna S Lok; Federico Hinestrosa; Paul J Thuluvath; Howard Schwartz; David R Nelson; Gregory T Everson; Timothy Eley; Megan Wind-Rotolo; Shu-Pang Huang; Min Gao; Dennis Hernandez; Fiona McPhee; Diane Sherman; Robert Hindes; William Symonds; Claudio Pasquinelli; Dennis M Grasela
Journal:  N Engl J Med       Date:  2014-01-16       Impact factor: 91.245

10.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Authors:  Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

View more
  5 in total

1.  HCV Screening and Treatment Uptake Among Patients in HIV Care During 2014-2015.

Authors:  Daniel Radwan; Edward Cachay; Oluwaseun Falade-Nwulia; Richard D Moore; Ryan Westergaard; William Christopher Mathews; Judith Aberg; Laura Cheever; Kelly A Gebo
Journal:  J Acquir Immune Defic Syndr       Date:  2019-04-15       Impact factor: 3.731

Review 2.  Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure.

Authors:  Meredith E Clement; Lauren F Collins; Julius M Wilder; Michael Mugavero; Taryn Barker; Susanna Naggie
Journal:  Infect Dis Clin North Am       Date:  2018-06       Impact factor: 5.982

3.  Awareness and knowledge of hepatitis C among health care providers and the public: A scoping review.

Authors:  S Ha; K Timmerman
Journal:  Can Commun Dis Rep       Date:  2018-07-05

4.  Characteristics and Specialist Linkage to Care of Patients Diagnosed With Chronic Hepatitis C Across Different Settings in an Urban Academic Hospital: Implications for Improving Diagnosis and Linkage to Care.

Authors:  Dan C S Im; Susheel Reddy; Claudia Hawkins; Shannon Galvin
Journal:  Front Microbiol       Date:  2021-02-11       Impact factor: 5.640

5.  Cost of Hepatitis C care facilitation for HIV/Hepatitis C Co-infected people who use drugs.

Authors:  Sarah Gutkind; Laura E Starbird; Sean M Murphy; Paul A Teixeira; Lauren K Gooden; Tim Matheson; Daniel J Feaster; Mamta K Jain; Carmen L Masson; David C Perlman; Carlos Del Rio; Lisa R Metsch; Bruce R Schackman
Journal:  Drug Alcohol Depend       Date:  2022-01-10       Impact factor: 4.852

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.